Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transgene plots a course through the cancer vaccine graveyard

This article was originally published in Scrip

Executive Summary

French gene and cellular therapy company,Transgene, has developed a triple-pronged strategy that, the company hopes, will help its cancer vaccine, TG4010, steer successfully through clinical trial that are due to start later in 2011. Professor Angus Dalgleish, a key clinical advisor to Transgene, told Scrip at the company’s R&D day at the end of May that the key to avoiding earlier failures with cancer vaccines lay in judicious patient selection, early administration and their use in combination with radio and chemotherapy.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts